Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. SPY
2. AVAV
3. NVDA
4. EOSE
5. NKE
6. MU
7. DLR
8. AAPL
9. TSLA
10. VSH

Go back to Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

Mizuho Securities Reiterates Buy Rating on Pfizer (PFE) After Speaking with Management

May 18, 2020 7:01 AM EDT

Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $42.00 price target on Pfizer (NYSE: PFE) following a conference call with management. Pfizer released updated data on their Duchenne Muscular Dystrophy (DMD) candidate at ASGCT.

Divan's overall conclusion is unchanged in that the... More